PURPOSE: To investigate the association of open-angle glaucoma (OAG), primary open-angle glaucoma (POAG), and pseudoexfoliative glaucoma (PEXG) with ocular perfusion pressure status (ocular perfusion pressure with or without antihypertensive treatment). DESIGN: Cross-sectional, population-based study. METHODS: A total of 2554 randomly selected, ≥ 60-year old subjects participated in the Thessaloniki Eye Study. Only clinic-visit participants (n = 2261), who had uniformly collected data, were included in the analyses. A logistic regression model was run for OAG in all clinic-visit participants; covariates included age, sex, diastolic ocular perfusion pressure, antihypertensive treatment, intraocular pressure (IOP), IOP-lowering treatment, pseudoexfoliation, and vascular factors identified as risk factors for glaucoma in a previous analysis. Similar logistic regression models were run separately for POAG and PEXG. In addition, logistic regression models were run for OAG, POAG, and PEXG in subjects with and without antihypertensive treatment. Also, logistic regression models were run to assess the role of systolic ocular perfusion pressure in OAG, POAG, and PEXG. RESULTS: Among clinic-visits, 1212 subjects (53.7%) were using antihypertensive treatment. An association of borderline significance was found between low diastolic ocular perfusion pressure and POAG (OR = 0.84 per 10 mm Hg, 95% CI = 0.70-1.01, P = .059). The effect of antihypertensive treatment on POAG was not statistically significant (OR = 1.20, 95% CI = 0.75-1.91, P = .45). In subgroup analyses, diastolic ocular perfusion pressure was significantly associated with POAG in subjects using antihypertensive treatment (OR = 0.78 per 10 mm Hg, 95% CI = 0.62-0.97, P = .028). No association was found between diastolic ocular perfusion pressure and PEXG, regardless of the use of antihypertensive treatment. No associations were found between systolic ocular perfusion pressure and OAG, POAG, or PEXG, regardless of the use of antihypertensive treatment. CONCLUSIONS: Low diastolic ocular perfusion pressure may be associated with increased risk for POAG. This association was confirmed in subjects treated for systemic hypertension in subgroup analysis. This may support the hypothesis that the concept of ocular perfusion pressure status may be more relevant to glaucoma pathogenesis than ocular perfusion pressure alone.
PURPOSE: To investigate the association of open-angle glaucoma (OAG), primary open-angle glaucoma (POAG), and pseudoexfoliative glaucoma (PEXG) with ocular perfusion pressure status (ocular perfusion pressure with or without antihypertensive treatment). DESIGN: Cross-sectional, population-based study. METHODS: A total of 2554 randomly selected, ≥ 60-year old subjects participated in the Thessaloniki Eye Study. Only clinic-visit participants (n = 2261), who had uniformly collected data, were included in the analyses. A logistic regression model was run for OAG in all clinic-visit participants; covariates included age, sex, diastolic ocular perfusion pressure, antihypertensive treatment, intraocular pressure (IOP), IOP-lowering treatment, pseudoexfoliation, and vascular factors identified as risk factors for glaucoma in a previous analysis. Similar logistic regression models were run separately for POAG and PEXG. In addition, logistic regression models were run for OAG, POAG, and PEXG in subjects with and without antihypertensive treatment. Also, logistic regression models were run to assess the role of systolic ocular perfusion pressure in OAG, POAG, and PEXG. RESULTS: Among clinic-visits, 1212 subjects (53.7%) were using antihypertensive treatment. An association of borderline significance was found between low diastolic ocular perfusion pressure and POAG (OR = 0.84 per 10 mm Hg, 95% CI = 0.70-1.01, P = .059). The effect of antihypertensive treatment on POAG was not statistically significant (OR = 1.20, 95% CI = 0.75-1.91, P = .45). In subgroup analyses, diastolic ocular perfusion pressure was significantly associated with POAG in subjects using antihypertensive treatment (OR = 0.78 per 10 mm Hg, 95% CI = 0.62-0.97, P = .028). No association was found between diastolic ocular perfusion pressure and PEXG, regardless of the use of antihypertensive treatment. No associations were found between systolic ocular perfusion pressure and OAG, POAG, or PEXG, regardless of the use of antihypertensive treatment. CONCLUSIONS: Low diastolic ocular perfusion pressure may be associated with increased risk for POAG. This association was confirmed in subjects treated for systemic hypertension in subgroup analysis. This may support the hypothesis that the concept of ocular perfusion pressure status may be more relevant to glaucoma pathogenesis than ocular perfusion pressure alone.
Authors: Jae H Kang; Stephanie J Loomis; Bernard A Rosner; Janey L Wiggs; Louis R Pasquale Journal: Invest Ophthalmol Vis Sci Date: 2015-04 Impact factor: 4.799
Authors: Alon Harris; Giovanna Guidoboni; Brent Siesky; Sunu Mathew; Alice C Verticchio Vercellin; Lucas Rowe; Julia Arciero Journal: Prog Retin Eye Res Date: 2020-01-24 Impact factor: 21.198
Authors: Hugues Aschard; Jae H Kang; Adriana I Iglesias; Pirro Hysi; Jessica N Cooke Bailey; Anthony P Khawaja; R Rand Allingham; Allison Ashley-Koch; Richard K Lee; Sayoko E Moroi; Murray H Brilliant; Gadi Wollstein; Joel S Schuman; John H Fingert; Donald L Budenz; Tony Realini; Terry Gaasterland; William K Scott; Kuldev Singh; Arthur J Sit; Robert P Igo; Yeunjoo E Song; Lisa Hark; Robert Ritch; Douglas J Rhee; Vikas Gulati; Shane Haven; Douglas Vollrath; Donald J Zack; Felipe Medeiros; Robert N Weinreb; Ching-Yu Cheng; Daniel I Chasman; William G Christen; Margaret A Pericak-Vance; Yutao Liu; Peter Kraft; Julia E Richards; Bernard A Rosner; Michael A Hauser; Caroline C W Klaver; Cornelia M vanDuijn; Jonathan Haines; Janey L Wiggs; Louis R Pasquale Journal: Eur J Hum Genet Date: 2017-08-30 Impact factor: 5.351
Authors: Luca Rossetti; Matteo Sacchi; Costas H Karabatsas; Fotis Topouzis; Michele Vetrugno; Marco Centofanti; Andreas Boehm; Christian Vorwerk; David Goldblum; Paolo Fogagnolo Journal: BMC Ophthalmol Date: 2015-01-22 Impact factor: 2.209